PTPRC and ovarian carcinoma: A more recent study investigating drug-resistant tumor cell phenotypes in the ascitic fluid of epithelial ovarian cancer patients identified that a population of cells that were EpCAM+CD45+ were more resistant compared to EpCAM+ tumor cells and overexpressed ABCA1[57].